drugset / Trial / NCT03633461

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

NCT03633461 ↗

Phase 2 Completed 53 enrolled Oyster Point Pharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety and effectiveness of OC-02 nasal spray compared to placebo on signs and symptoms of dry eye disease (DED).

Timeline

Start
2018-08-14
Primary completion
2018-09-20
Completion
2018-09-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator simpinicline Small molecule 11.1 mg/ml Intranasal

Indications